Genome Canada Statement of operations and changes in net assets year ended March 31, 2017 (in thousands of dollars) 2017 2016 $ $ Revenues Amortization of deferred contributions (Note 6) 62,162 53,039 Amortization of deferred contributions related to capital assets (Note 7) 53 50 62,215 53,089 Expenses Projects and Genome Centres 55,419 45,850 Program management 2,001 2,177 Strategy, Development and External Relations 2,444 2,273 Corporate Services 2,298 2,739 Amortization of capital assets 53 50 62,215 53,089 Excess of revenues over expenses, being net assets, end of year - - See accompanying notes to financial statements Page 3